bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-71-3417

Order Name:
Caris - MI Tumor seek & PD-L1, tissue (FFPE) **

 
Useful For:
MI Tumor Seek (test by NGS), plus PD-L1 testing.

PD-1 (test by IHC) is an immunosuppressive protein molecule that is upregulated on activated T-cells and other immune cells. It is activated by binding to its ligand, PD-L1, an action that results in intracellular responses that reduce T-cell activation. Reports of aberrant PD-L1 expression in cancer cells have spurred the development of PD-1 and PD-L1 inhibitors. The U.S. Food and Drug Administration (FDA) recently approved an anti-PD-1 therapy, pembrolizumab (Keytruda), for the treatment of advanced or unresectable melanoma. Another anti-PD-1 agent, nivolumab, was recently approved in Japan for the treatment of unresectable melanoma.
 
Methodology:
Next-generation sequencing (NGS)
 
Test List In Profile:
All Biomarker Analysis includes:
DNA Mutation, Copy Number Alterations, Insertions/Deletions    
Genomic Signatures: MSI, TMB
RNA Fusion Analysis
IHC: PD-L1
 
AliasesName:
Comprehensive Genomic Profiling, Tissue
 
 
 
Test Code:
090-71-3417

Order Name:
Caris - MI Tumor seek & PD-L1, tissue (FFPE) **

 
Collection Specimen Or Container:
Tissue/ Formalin-fixed paraffin-embedded (FFPE) block
 
Specimen Testing Type:
NGS: FFPE block or 10 unstained slides with a minimum of 20% malignant origin for DNA and 10% malignant origin for RNA. Needle biopsy is also acceptable (4-6 cores).
IHC: 1 unstained slide at 4μm thickness from FFPE block, with evaluable tumor present, per IHC test
 
Sub Mission Container:
Specimen collection kit
 
Rejection Criteria:
Specimen was insufficient for testing (Low cellularity, Low tumor purity, DNA highly fragmentation, Low of RNA quality)
 
 
 
Test Code:
090-71-3417

Order Name:
Caris - MI Tumor seek & PD-L1, tissue (FFPE) **

 
Method detail:
Next-generation sequencing (NGS)
 
Schedule:
N/A **Sent out to Caris, USA
 
Turnaround Time:
Received specimen to report 20-30 days (Slide received to report)
 
Performing Location:
Caris Life Sciences, USA
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code:
090-71-3417

Order Name:
Caris - MI Tumor seek & PD-L1, tissue (FFPE) **

 
 
Reference Value:
An interpretive report will be provided.
 
Clinical Reference:
www.carislifesciences.com (Retrieved: 25 Jun 2020)